With the cases of Coronavirus increasing at a rapid pace throughout the world, Therapeutic company Sorrento has some good news to share with the world. The company released a statement, detailing its preclinical research, on Friday and announced the presence of an antibody that provides “100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation.”

SARS-CoV-2 is the virus that leads to Coronavirus, and the antibody found is likely to be effective in treating the root cause of the infection. Though the results seem to make a huge difference in controlling the COVID-19 cases, it is yet to undergo peer review. The experiment was an in vitro laboratory study but is being considered as one of the most promising developments until now. The company observed the presence of the antibody while it continued working on the production of a “cocktail” antibody that could offer protection against the infection despite the mutations in the virus.

“Sorrento has determined STI-1499 will likely be the first antibody in the antibody cocktail (COVI-SHIELDTM) it is developing, as recently announced,” the company stated last week while announcing its plan to develop the cocktail treatment for patients of COVID-19 in collaboration with Mount Sinai Health System. “STI-1499 is also expected to be developed as a stand-alone therapy” (COVI-GUARDTM) because of the high potency it has exhibited in experiments to date.

The company said that it believes that the antibody from the extensive human antibody library of billions of candidates has been identified uniquely for its ability to block the interaction of the virus with a human cell receptor completely. As a result, it surely prevents the virus from getting attached to the healthy cells of the hosts, thereby removing the chances of further incubation or infection. Sorrento indicated that the antibody discovered will be the first one to be included in the cocktail it has been working on to develop. The cocktail, as the name suggests, will be made of multiple antibodies that will provide protection against the infection by blocking the attachment of the spike protein to the healthy cells of an individual’s body.

The cocktail, in addition, will also be designed to be effective enough even if the virus mutates while getting transmitted from one person to another or within the same individual. The treatment may not be a “magic bullet,” but it will be a promising development for sure.